Accretion/amortization of investments, net Unrealized Gain (Loss) on Investments Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Rights retained Advance Future Royalties, Retained Rights After Annual Sales Threshold Exceeded Advance Future Royalties, Retained Rights After Annual Sales Threshold Exceeded Award Timing Predetermined Award Timing Predetermined [Flag] 2025 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Entity File Number Entity File Number Additional Paid-in Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Earnings Per Share, Basic [Abstract] Earnings Per Share, Basic [Abstract] Proceeds from the sale of future royalties Proceeds From Sale Of Advance Future Royalties Proceeds From Sale Of Advance Future Royalties Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Number of shares, Restricted stock units expected to vest (in dollars per share) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value Commercial sales first exceed $100.0 million Commercial Sales Milestone [Member] Commercial Sales Milestone License License [Member] Stock awards Share-Based Payment Arrangement [Member] Net share settlement of restricted stock units Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] PD-1 (Jemperli/Dostarlimab) AnaptysBio-generated Anti-PD-1 (Jemperli/Dostarlimab) [Member] AnaptysBio-generated Anti-PD-1 (Jemperli/Dostarlimab) Basic (in dollars per share) Net income (loss) per share, basic (in dollars per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Liabilities Related To Sale Of Future Royalties [Line Items] Liabilities Related To Sale Of Future Royalties [Line Items] Liabilities Related To Sale Of Future Royalties Schedule of Milestones Achieved Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] By the end of 2026 First Installment [Member] First Installment Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Preclinical and other unallocated costs Preclinical And Other Unallocated Costs [Member] Preclinical And Other Unallocated Costs Schedule of Segment Revenue, Loss and Significant Expenses Schedule of Segment Reporting Information, by Segment [Table Text Block] Issuance of common stock upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Area of leased property (sqft) Area of Real Estate Property Schedule of Available-for-sale Investments Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Issued under ESPP (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued Basis of Consolidation Consolidation, Policy [Policy Text Block] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Options to purchase common stock Stock Options Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Income taxes paid Income Taxes Paid Antidilutive Securities [Axis] Antidilutive Securities [Axis] Total stockholders’ (deficit) equity Stockholders' equity, beginning balance Stockholders' equity, ending balance Equity, Attributable to Parent Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Insider Trading Policies and Procedures [Line Items] Total Share-Based Payment Arrangement, Expense Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized GSK GlaxoSmithKline [Member] GlaxoSmithKline Issuance of common stock, net of transaction costs (in shares) Stock Issued During Period, Shares, New Issues Current assets: Assets, Current [Abstract] Total liabilities and stockholders’ (deficit) equity Liabilities and Equity First MAA approval - first indication First Marketing Authorization Application Approval - First Indication [Member] First Marketing Authorization Application Approval - First Indication Recurring Fair Value, Recurring [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Shares Subject to Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Liabilities and Equity [Abstract] IND clearance from the FDA Clearance Of Investigational New Drug From FDA [Member] Clearance Of Investigational New Drug From FDA [Member] Cover [Abstract] Cover [Abstract] Investments at fair value Cash and Cash Equivalents, Fair Value Disclosure Reimbursement Reimbursement Payments to Acquire Productive Assets Reimbursement Payments to Acquire Productive Assets Monthly base rate (in dollars per sqft) Rent Per Square Foot Rent Per Square Foot Maximum Maximum [Member] General and administrative General and Administrative Expense [Member] Weighted-average exercise price per share, Stock options exercisable, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Accounting Policies [Abstract] Accounting Policies [Abstract] Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position Schedule of Future Minimum Annual Obligations Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Remaining maturity (in years) Available-for-sale Debt Securities, Remaining Maturity Available-for-sale Debt Securities, Remaining Maturity Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Lease liability Total Operating Lease, Liability Agency securities US Government Agencies Debt Securities [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income (loss) before income taxes Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Regulatory approval for marketing of the first licensed product in the EU Regulatory Approval For Marketing Of The First Licensed Product In The EU [Member] Regulatory Approval For Marketing Of The First Licensed Product In The EU JEMPERLI Royalty Monetization Agreement JEMPERLI Royalty Monetization Agreement [Member] JEMPERLI Royalty Monetization Agreement Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Name Measure Name Current portion of operating lease liability Operating Lease, Liability, Current Filing of the first BLA - second indication Filing of Biologics License Application - Second Indication [Member] Filing of Biologics License Application - Second Indication Class of Stock [Line Items] Class of Stock [Line Items] ANB033 ANB033 [Member] ANB033 Document Fiscal Period Focus Document Fiscal Period Focus Award Timing Method Award Timing Method [Text Block] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Award Type [Axis] Award Type [Axis] First BLA approval - first indication First Biologics License Application Approval - dMMREC [Member] First Biologics License Application Approval - dMMREC Total assets Assets Trading Symbol Trading Symbol 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four Aggregate intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Released (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value First MAA approval - second indication First Marketing Authorization Application Approval - Second Indication [Member] First Marketing Authorization Application Approval - Second Indication Entity Address, City or Town Entity Address, City or Town CASH FLOWS FROM OPERATING ACTIVITIES: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Income Statement Location [Domain] Statement of Income Location, Balance [Domain] RSUs Restricted Stock Units (RSUs) [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Research and development Research and Development Expense (Excluding Acquired in Process Cost) Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Stock options outstanding, beginning balance (in shares) Stock options outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Royalty Agreement, Above $2.5 billion Royalty Agreement, Above $2.5 billion [Member] Royalty Agreement, Above $2.5 billion Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Common stock, shares outstanding (in shares) Stockholders' equity, beginning balance (in shares) Stockholders' equity, ending balance (in shares) Common Stock, Shares, Outstanding Plan Name [Axis] Plan Name [Axis] Liabilities Related To Sale Of Future Royalties [Table] Liabilities Related To Sale Of Future Royalties [Table] Liabilities Related To Sale Of Future Royalties PEO PEO [Member] Royalties and milestones, agreement amount to be received Advance Future Royalties, Aggregate Additional Payment Advance Future Royalties, Aggregate Additional Payment Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accumulated Deficit Retained Earnings [Member] Potential future payments Asset Acquisition, Contingent Consideration Arrangements, Range of Outcomes, Value, High Asset Acquisition, Contingent Consideration Arrangements, Range of Outcomes, Value, High Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Proceeds from sale of future royalties Proceeds From Advance Future Royalties Proceeds From Advance Future Royalties Number of Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) 12 months or greater, Fair value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Sale of Stock [Domain] Sale of Stock [Domain] Royalties Royalty Agreement [Member] Royalty Agreement Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Royalties and milestones received Cumulative Repayment Of Advance Future Royalty And Milestones Cumulative Repayment Of Advance Future Royalty And Milestones Product and Service [Domain] Product and Service [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Property and equipment, gross Property, Plant and Equipment, Gross Schedule of Performance Shares, Outstanding Activity Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Royalty Agreement, Above $1. 0 billion Below $1.5 Billion Royalty Agreement, Above $1. 0 billion Below $1.5 Billion [Member] Royalty Agreement, Above $1. 0 billion Below $1.5 Billion Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Sagard Sagard Healthcare Royalty Partners, LP [Member] Sagard Healthcare Royalty Partners, LP Amortization of right-of-use assets – operating Operating Lease, Right-of-Use Asset, Periodic Reduction Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Proceeds from stock options exercised Proceeds from Stock Options Exercised City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accrued for repurchases of common stock Accrued Common Stock Repurchased Accrued Common Stock Repurchased Accrued expenses Total accrued expenses Accrued Liabilities, Current Number of shares, beginning balance (in shares) Number of shares, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Royalty Transaction Activity Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] CASH FLOWS FROM INVESTING ACTIVITIES: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] General and administrative General and Administrative Expense Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Imsidolimab Imsidolimab [Member] Imsidolimab Amounts accrued for offering costs Offering Costs Incurred but Not yet Paid Offering Costs Incurred but Not yet Paid Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Award equivalent shares Share-based Compensation Arrangement by Share-based Payment Award, Common Share Equivalent Share-based Compensation Arrangement by Share-based Payment Award, Common Share Equivalent Schedule of Weighted Average Assumptions used to Estimate Fair Value Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Schedule of Non-Cancellable Office Lease Costs Lease, Cost [Table Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Exclusive License Agreement Exclusive License Agreement [Member] Exclusive License Agreement Money market funds Money Market Funds [Member] Denominator: Weighted Average Number of Shares Outstanding, Basic [Abstract] Equity Components [Axis] Equity Components [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Description of the Business Nature of Operations [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Royalty Agreement, Above $1. 5 billion Below $2.5 Billion Royalty Agreement, Above $1.5 billion Below $2.5 Billion [Member] Royalty Agreement, Above $1.5 billion Below $2.5 Billion Number of reportable segments Number of Reportable Segments Lessee, operating lease, termination fee Lessee, Operating Lease, Termination Fee Lessee, Operating Lease, Termination Fee SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other Performance Measure, Amount Other Performance Measure, Amount Weighted-Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Payments for debt issuance costs Payments of Debt Issuance Costs Entity Address, State or Province Entity Address, State or Province Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total current liabilities Liabilities, Current Individual: Individual [Axis] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Research and development Research and Development Expense [Member] Net cash provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Interest portion of repayment for sale of future royalties Interest Paid, Excluding Capitalized Interest, Operating Activity Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] FDA regulatory approval for marketing of first licensed product in the USA for the treatment of active flares in GPP FDA Regulatory Approval For Marketing Of First Licensed Product In The USA For The Treatment Of Active Flares In GPP [Member] FDA Regulatory Approval For Marketing Of First Licensed Product In The USA For The Treatment Of Active Flares In GPP Entity Interactive Data Current Entity Interactive Data Current Operating lease cost Operating Lease, Cost Plan Name [Domain] Plan Name [Domain] Net sales royalty Commercial sales Net Sales Royalty Threshold Net Sales Royalty Threshold Weighted average period remaining for amortization of unrecognized compensation cost (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Mutual funds Mutual Fund [Member] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Equity [Abstract] Equity [Abstract] Earnings per share Earnings Per Share, Basic and Diluted EPS [Abstract] Earnings Per Share, Basic and Diluted EPS Aggregate intrinsic value, options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Schedule of Grant Date Fair Value Assumptions Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Segment Reporting Segment Reporting Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] U.S. Treasury Securities US Treasury Securities [Member] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Number of business independent Number Of Businesses After Spinoff Number Of Businesses After Spinoff Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Milestones that may be recognized in the future Milestones Yet To Be Recognized [Member] Milestones Yet To Be Recognized Cash payment Payments to Acquire Productive Assets Sale of Future Royalties Sale Of Future Royalties Text Block [Text Block] Sale Of Future Royalties Text Block Revenue recognition milestone annual sales threshold Revenue Recognition Milestone Annual Sales Threshold Revenue Recognition Milestone Annual Sales Threshold Depreciation and amortization Depreciation, Depletion and Amortization Centessa Pharmaceuticals (UK) Limited (Centessa) Centessa Pharmaceuticals (UK) Limited (Centessa) [Member] Centessa Pharmaceuticals (UK) Limited (Centessa) Other long-term assets Other Assets, Noncurrent Entity Central Index Key Entity Central Index Key PEO Name PEO Name Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Lease Agreement 10770 Wateridge Circle, San Diego, California 92121 [Member] 10770 Wateridge Circle, San Diego, California 92121 Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of shares, Restricted stock units expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Jemperli Royalty Monetization Agreement Amendment 1 Jemperli Royalty Monetization Agreement Amendment One [Member] Jemperli Royalty Monetization Agreement Amendment One Equity Incentive Plans Share-Based Payment Arrangement [Text Block] Repurchases and retirements of common stock (in shares) Stock Repurchased and Retired During Period, Shares Phase 2 clinical trial initiation Phase 2 Clinical Trial Initiation [Member] Phase 2 Clinical Trial Initiation [Member] ASSETS Assets [Abstract] Expected milestone payment Accrued Repayment Of Advance Future Sales Milestones Accrued Repayment Of Advance Future Sales Milestones Underlying Security Market Price Change Underlying Security Market Price Change, Percent Forfeitures and cancellations (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Fair Value Measurements and Available for Sale Investments Fair Value Disclosures [Text Block] Stockholders’ (deficit) equity: Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Approximate dollar value of shares purchased (in dollars per share) Treasury Stock, Value, Acquired, Cost Method Research and development Research and Development Expense Accumulated Other Comprehensive Gain (Loss) AOCI Attributable to Parent [Member] Net share settlement of restricted stock units (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Name of Property [Domain] Name of Property [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Entity Registrant Name Entity Registrant Name GlaxoSmithKline Collaboration Collaborative Arrangement [Member] Issuance of common stock from exercises of options and employee stock purchase plan Stock Issued During Period, Value, Options and Employee Stock Purchase Plan Stock Issued During Period, Value, Options and Employee Stock Purchase Plan Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Open Market Sales Agreement Open Market Sales Agreement [Member] Open Market Sales Agreement Reportable Segment Research and Development Segment [Member] Research and Development Segment Weighted average number of shares outstanding, diluted, adjustment (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Title of Individual [Domain] Title and Position [Domain] Commercial and corporate obligations Commercial And Corporate Obligations [Member] Commercial And Corporate Obligations [Member] Forfeitures and cancellations (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Document Quarterly Report Document Quarterly Report Less than 12 months, Fair value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Annual increase in number of shares available for issuance percentage (as a percent) Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Weighted average remaining contractual term, options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Zejula revenue prior to the Zejula Royalty Monetization Agreement Zejula Revenue [Member] Zejula Revenue Existing drug supply Drug Supply [Member] Drug Supply Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Non-PEO NEO Non-PEO NEO [Member] Aggregate intrinsic value, options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Accrued research, development and manufacturing expenses Accrued Research And Development Expenses, Current Accrued Research And Development Expenses, Current First BLA approval - second indication First Biologics License Application Approval - Second Indication [Member] First Biologics License Application Approval - Second Indication Underwriting discounts and commissions and offering expenses Payments Of Stock Issuance Costs And Underwriting Discounts And Commissions Payments Of Stock Issuance Costs And Underwriting Discounts And Commissions Interest income Interest Income, Other Sale of Stock [Axis] Sale of Stock [Axis] Weighted average remaining contractual term, other than options vested and expected to vest (in years) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Remaining Contractual Terms Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Remaining Contractual Terms Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Name Trading Arrangement, Individual Name Award Type [Domain] Award Type [Domain] 2026 Lessee, Operating Lease, Liability, to be Paid, Year One Equity Awards Adjustments Equity Awards Adjustments [Member] Leasehold improvements Leasehold Improvements [Member] Non-cash interest expense Other Noncash Income (Expense) Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Phase 3 clinical trial initiation - first indication Phase 3 Clinical Trial Initiation - First Indication [Member] Phase 3 Clinical Trial Initiation - First Indication Compensation Amount Outstanding Recovery Compensation Amount Royalties agreement, maximum annual royalty payout capacity Advance Future Royalties, Annual Sales Threshold Advance Future Royalties, Annual Sales Threshold Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Aggregate intrinsic value, restricted stock units expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Settlement agreement rate (as a percent) Advance Future Royalties, Minimum Global Net Sales, Rate Advance Future Royalties, Minimum Global Net Sales, Rate Milestones that may be recognized in the future Revenue Recognition, Milestone Method, Contingent Revenue Recognition, Milestone Method, Contingent Zejula Royalty Monetization Agreement Zejula Royalty Monetization Agreement [Member] Zejula Royalty Monetization Agreement MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Transaction costs incurred Asset Acquisition, Consideration Transferred, Transaction Cost Weighted average grant date fair value, beginning balance (in dollars per share) Weighted average grant date fair value, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted-average number of shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Principal repayment of liability for sale of future royalties Royalty and milestone payments to Sagard Repayment Of Advance Future Royalty And Milestones Repayment Of Advance Future Royalty And Milestones Lessee, operating lease, termination period (in months) Lessee, Operating Lease, Termination Period Lessee, Operating Lease, Termination Period ESPP Employee Stock [Member] Milestone revenue recognition Contract with Customer, Timing of Satisfaction of Performance Obligation and Payment Accumulated other comprehensive gain Accumulated Other Comprehensive Income (Loss), Net of Tax Financial Instruments [Domain] Financial Instruments [Domain] Unrealized gain (loss) on available for sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Segments [Domain] Segments [Domain] Royalty percent on net sales (as a percent) Net Sales Royalty, Percent Net Sales Royalty, Percent Income Statement Location [Axis] Statement of Income Location, Balance [Axis] PSU Performance Shares [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Non-cash interest expense for the sale of future royalties Non-cash interest expense Non-cash interest expense recognized Non-cash interest expense Noncash Advance Future Royalties, Interest Expense Noncash Advance Future Royalties, Interest Expense Minimum Minimum [Member] Security deposit Security Deposit Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Net Income (Loss) Per Common Share Earnings Per Share, Policy [Policy Text Block] Company Selected Measure Name Company Selected Measure Name Purchases of investments Payments to Acquire Debt Securities, Available-for-Sale Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at September 30, 2025 and December 31, 2024, respectively Preferred Stock, Value, Issued Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Business separation, expected period Business Separation, Capitalization Period Business Separation, Capitalization Period Proceeds from stock plans Proceeds from Stock Plans Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Common stock, $0.001 par value, 500,000 shares authorized, 27,575 shares and 30,473 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively Common Stock, Value, Issued Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Title of Individual [Axis] Title and Position [Axis] Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted average remaining contractual term, other than options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Entity Small Business Entity Small Business Payments for offering costs Payments of Stock Issuance Costs Filing of the first MAA - second indication Filing of MMA - Second Indication [Member] Filing of MMA - Second Indication Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Document Transition Report Document Transition Report Transaction costs expensed Collaborative Arrangement Costs Collaborative Arrangement Costs Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Issuance of common stock from exercises of options and employee stock purchase plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options And Employee Stock Purchase Plan Share-based Compensation Arrangement by Share-based Payment Award, Options And Employee Stock Purchase Plan Underlying Securities Award Underlying Securities Amount Advance Future Royalties, Payment [Axis] Advance Future Royalties, Payment [Axis] Advance Future Royalties, Payment Amounts accrued for repurchases of common stock Repurchase of Common Stock Incurred But Not Yet Paid Repurchase of Common Stock Incurred But Not Yet Paid Underwritings Underwriting Agreement [Member] Underwriting Agreement Equity Component [Domain] Equity Component [Domain] Phase 3 clinical trial initiation - second indication Phase 3 clinical Trial Initiation - Second Indication [Member] Phase 3 clinical Trial Initiation - Second Indication [Member] Document Period End Date Document Period End Date PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Forfeitures and cancellations (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Receivable related to issuance of common stock, upon exercise of stock options Receivables for Stock Options Exercised Receivables for Stock Options Exercised Balance Sheet Accounts and Supplemental Disclosures Supplemental Balance Sheet Disclosures [Text Block] Non-cash interest expense capitalized Noncash Interest Expense, Negative Amortization Noncash Interest Expense, Negative Amortization Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Revenue from Contract with Customer [Abstract] Advance Future Royalties, Payment [Domain] Advance Future Royalties, Payment [Domain] Advance Future Royalties, Payment [Domain] Weighted average remaining contractual term, options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Operating lease liabilities Increase (Decrease) in Operating Lease Liability Average price paid per share (in dollars per share) Shares Acquired, Average Cost Per Share Proceeds from public offerings, net of underwriters’ fees Proceeds From Issuance Of Public Offering Proceeds From Issuance Of Public Offering Jemperli Royalty Monetization Agreement Jemperli Royalty Monetization Agreement [Member] Jemperli Royalty Monetization Agreement Document Type Document Type Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Name Outstanding Recovery, Individual Name Additional paid in capital Additional Paid in Capital Product and Service [Axis] Product and Service [Axis] Office furniture and equipment Office Equipment [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Number of shares issuable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Shares Issuable Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Shares Issuable All Individuals All Individuals [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Total transferred Asset Acquisition, Consideration Transferred Name Forgone Recovery, Individual Name Increase in annual rent (as a percent) Annual Rent Increase, Percent Annual Rent Increase, Percent Award expiration period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] ANB032 ANB032 [Member] ANB032 Other Liabilities Disclosure [Abstract] Forfeitures and cancellations (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Authorized repurchase amount Share Repurchase Program, Authorized, Amount Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Equity Incentive Plan, 2017 Equity Incentive Plan, 2017 [Member] Equity Incentive Plan, 2017 [Member] Payment for net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Liability related to sale of future royalties Advance Future Royalties, Liability, Noncurrent Advance Future Royalties, Liability, Noncurrent Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Comprehensive gain (loss), net Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Current liabilities: Liabilities, Current [Abstract] Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Total operating expenses Total operating expenses Operating Expenses Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Liabilities Related To Sale Of Future Royalties [Roll Forward] Liabilities Related To Sale Of Future Royalties [Roll Forward] Liabilities Related To Sale Of Future Royalties Quoted Market Prices for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Diluted (in dollars per share) Net income (loss) per share, diluted (in dollars per share) Earnings Per Share, Diluted Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Title of 12(b) Security Title of 12(b) Security Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Filing of the first MAA - first indication Filing of MMA - First Indication [Member] Filing of MMA - First Indication Shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Employee Stock Purchase Plan, 2017 Employee Stock Purchase Plan, 2017 [Member] Employee Stock Purchase Plan, 2017 [Member] Stock-based compensation APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Net income (loss) per common share: Earnings Per Share [Abstract] Total other expense, net Total other expense, net Nonoperating Income (Expense) Filing of the first BLA - first indication Filing of Biologics License Application - First Indication [Member] Filing of Biologics License Application - First Indication Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Short-term investments Debt Securities, Available-for-Sale, Current Repurchases and retirements of common stock Stock Repurchased and Retired During Period, Value Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lease termination term (in years) Lessee, Operating Lease, Expiration Period Lessee, Operating Lease, Expiration Period Total number of shares purchased (in shares) Treasury Stock, Shares, Acquired Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Award Timing Disclosures [Line Items] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Measurement Frequency [Domain] Measurement Frequency [Domain] Net of proceeds Advance Future Royalties, Liability, Noncurrent, Net Advance Future Royalties, Liability, Noncurrent, Net Accrued compensation and related expenses Employee-related Liabilities, Current Total minimum payments required Lessee, Operating Lease, Liability, to be Paid Lease renewal term (in years) Lessee, Operating Lease, Renewal Term Stockholders' Equity Equity [Text Block] Royalty Agreement, Up To $1.0 billion Royalty Agreement, Up To $1. 0 billion [Member] Royalty Agreement, Up To $1. 0 billion Net income (loss) Net loss Net loss Segment net income (loss) Net Income (Loss) Attributable to Parent Schedule of Unrealized Loss and Fair Values in a Loss Position Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Expiration Date Trading Arrangement Expiration Date DRI Healthcare Trust DRI Healthcare Trust [Member] DRI Healthcare Trust Second commercial sales milestone Second Commercial Sales Milestone [Member] Second Commercial Sales Milestone Aggregate offering of (up to) Sale of Stock, Authorized Aggregate Offering, Maximum Sale of Stock, Authorized Aggregate Offering, Maximum Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vanda Vanda Pharmaceuticals Inc. [Member] Vanda Pharmaceuticals Inc. Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Beginning balance Ending balance Advance Future Royalties, Liabilities Advance Future Royalties, Liabilities Repurchase and retirements of common stock Payments for Repurchase of Common Stock Adoption Date Trading Arrangement Adoption Date Share price (in dollars per share) Shares Issued, Price Per Share Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Entity Current Reporting Status Entity Current Reporting Status Lease term (in months) Lessee, Operating Lease, Term of Contract Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Income (loss) from operations Net income (loss) from operations Operating Income (Loss) Accumulated deficit Retained Earnings (Accumulated Deficit) Schedule of Stock Repurchase Activity Class of Treasury Stock [Table Text Block] Name of Property [Axis] Name of Property [Axis] Daniel Faga [Member] Daniel Faga Schedule of Non-cash Stock-based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] 12 months or greater, Gross unrealized losses Unrealized losses on available for sale investments in unrealized loss position for greater than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Effective interest rate (as a percent) Advance Future Royalties, Interest Rate, Effective Percentage Advance Future Royalties, Interest Rate, Effective Percentage Fourth commercial sales milestone Fourth Commercial Sales Milestone [Member] Fourth Commercial Sales Milestone Current Fiscal Year End Date Current Fiscal Year End Date Issuance costs related to the sale of future royalties Advance Future Royalties, Issuance Costs Advance Future Royalties, Issuance Costs Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Less than 12 months, Gross unrealized losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Shares reserved for future award grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Statement [Table] Statement [Table] Other (expense) income, net Other Nonoperating Income (Expense) Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Collaborative Research and Development Agreements Collaborative Arrangement Disclosure [Text Block] CASH FLOWS FROM FINANCING ACTIVITIES: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Weighted average grant date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] License Agreement, Centessa Pharmaceuticals (UK) Limited License Agreement, Centessa Pharmaceuticals (UK) Limited [Member] License Agreement, Centessa Pharmaceuticals (UK) Limited Receivables from collaborative partners Receivables, Net, Current Gross
Unrealized Losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Options to purchase common stock (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount During 2027 Second Installment [Member] Second Installment All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Rosnilimab Rosnilimab [Member] Rosnilimab Termination Date Trading Arrangement Termination Date Net cash (used in) provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Receivables from collaborative partners Increase (Decrease) in Contract with Customer, Asset Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Number of milestone Number Of Milestones Acheived Number Of Milestones Acheived Internal Internal Expenses [Member] Internal Expenses Weighted-average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Schedule of Activity Related to Stock Option Awards Share-Based Payment Arrangement, Option, Activity [Table Text Block] Long-term investments Debt Securities, Available-for-Sale, Noncurrent Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Remaining repurchase amount Share Repurchase Program, Remaining Authorized, Amount Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Directors Director [Member] Shares subject to options, exercisable, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Transition services revenue Transaction Service [Member] Transaction Service Subsequent Events [Abstract] Subsequent Events [Abstract] Segment Reporting [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Other income (expense), net: Nonoperating Income (Expense) [Abstract] Entity Tax Identification Number Entity Tax Identification Number Asset Acquisition [Axis] Asset Acquisition [Axis] Stock options outstanding, beginning balance (in dollars per share) Stock options outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Amortization of issuance costs Amortization Of Advance Future Royalties Issuance Costs Amortization Of Advance Future Royalties Issuance Costs Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (in shares) Common Stock, Shares, Issued External External Expenses [Member] External Expenses Third commercial sales milestone Third Commercial Sales Milestone [Member] Third Commercial Sales Milestone Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Use of Estimates Use of Estimates, Policy [Policy Text Block] Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Upfront payment Collaborative Arrangement, Payment Collaborative Arrangement, Payment Subsequent Event Subsequent Events [Text Block] Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Milestones recognized through September 30, 2025 Cumulative Milestones Recognized [Member] Cumulative Milestones Recognized Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Amounts accrued for property and equipment Capital Expenditures Incurred but Not yet Paid Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Operating expenses: Operating Expenses [Abstract] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Agreement term following first commercial sale or expiration of the last to expire patent (in years) Revenue Recognition, Milestone Method, Commercial Sale Or Expiration Of Patents, Agreement Term Revenue Recognition, Milestone Method, Commercial Sale Or Expiration Of Patents, Agreement Term Issuance of common stock, net of transaction costs Stock Issued During Period, Value, New Issues Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] ANB101 ANB101 [Member] ANB101 Cash and cash equivalents Cash and Cash Equivalent First commercial sales milestone First Commercial Sales Milestone [Member] First Commercial Sales Milestone Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Time-based Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Number of additional shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Non-cash interest expense and amortization of issuance costs Noncash Advance Future Royalties And Amortization Of Advance Future Royalties, Interest Expense Noncash Advance Future Royalties And Amortization Of Advance Future Royalties, Interest Expense Common Stock Common Stock [Member] Released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Short and long-term investments Total Fair Value Debt Securities, Available-for-Sale Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Accrued professional fees and other expenses Accrued Professional Fees, Current Initiated in vivo toxicology studies using good laboratory practices (GLPs) In Vivo Toxicology Studies [Member] In Vivo Toxicology Studies [Member] Collaboration Revenue [Member] Collaboration Revenue